GOTHENBURG, SE / ACCESSWIRE / December 31, 2021 / IRLAB Therapeutics (STO: IRLAB-A) (FRA: 6IRA)
IRLAB (Nasdaq Stockholm: IRLAB A). Martin Nicklasson has announced his intention to step down from the board in January 2022. The background to this move is his new role as chairman of the board of another company.
According to the statutes of the IRLAB, the board of directors is made up of at least three (3) and at most (10) members. When Nicklasson leaves the Board of Directors, it will be composed of five (5) members and will therefore continue to fulfill this requirement until the next Annual General Meeting in May 2022, when a new Board of Directors is chosen.
“On behalf of the Board of Directors and the shareholders, I would like to warmly thank Martin for his valuable contribution to the activities of the Board of Directors over the past year,” said Gunnar Olsson, Chairman of the Board of Directors of ‘IRLAB. “2021 was a period of transformation in the development of the IRLAB. Our successful licensing agreement with mesdopetam and regulatory approvals for the start of the Phase IIb study with worstpemat have given us a whole new basis for achieving the long-term goals of IRIAB.
For more information
Gunnar Olsson, Chairman of the Board
Telephone: +46 70 576 14 02
Email: [email protected]
About the IRLAB
IRLAB is a Swedish research and development company focused on the discovery and development of new treatments for Parkinson’s disease. The company’s most advanced drug candidates, Mesdopetam (IRL790), licensed by Ipsen, and Pirepemat (IRL752), have completed Phase IIa studies and are designed to treat some of the most difficult symptoms associated with Parkinson’s disease : involuntary movements (PD-LID), psychosis (PD-P) and symptoms related to cognitive decline such as balance disorders and increased risk of falls (PD-Falls). Thanks to its proprietary research platform, the Integrative Screening Process (ISP), IRIBA has discovered and developed all of its projects in Parkinson’s disease and will have the capacity to also discover drug candidates for other disorders. central nervous system (CNS), where increasing medical needs exist. In addition to the Phase IIb clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical stages. IRLAB is listed on the Nasdaq Stockholm Main Market. You will find more information on www.irlab.se.
THE SOURCE: IRLAB Therapeutic
See the source version on accesswire.com: